Intact PTEN Expression by Immunohistochemistry is Associated With Decreased Survival in Advanced Stage Ovarian/Primary Peritoneal High-grade Serous Carcinoma

No abstract is available for this paper.

• Publication year

  2015

• Venue

  International Journal of Gynecological Pathology

• Publication date

  2015-11-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1097/PGP.0000000000000205PMID 26166715
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• KRAS Mutation as the Biomarker of Response to Chemotherapy and EGFR-TKIs in Patients With Advanced Non–Small Cell Lung Cancer: Clues For Its Potential Use in Second-Line Therapy Decision Making

  2015cited by this paper
• Type I to type II ovarian carcinoma progression: mutant Trp53 or Pik3ca confers a more aggressive tumor phenotype in a mouse model of ovarian cancer.

  2013cited by this paper
• Immunoexpression of the PTEN protein and matrix metalloproteinase-2 in endometrial cysts, endometrioid and clear cell ovarian cancer.

  2013cited by this paper
• PIK3CA overexpression is a possible prognostic factor for favorable survival in ovarian clear cell carcinoma.

  2013cited by this paper
• The Genomic Landscape of TP53 and p53 Annotated High Grade Ovarian Serous Carcinomas from a Defined Founder Population Associated with Patient Outcome

  2012cited by this paper
• The Association of PI3 Kinase Signaling and Chemoresistance in Advanced Ovarian Cancer

  2012cited by this paper
• Cancer statistics, 2012

  2012cited by this paper
• Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis.

  2011cited by this paper
• Evolution of platinum resistance in high-grade serous ovarian cancer.

  2011cited by this paper
• Frequent genetic abnormalities of the PI3K/AKT pathway in primary ovarian cancer predict patient outcome

  2011cited by this paper
• Clinical Assessment of PTEN Loss in Endometrial Carcinoma: Immunohistochemistry Out-Performs Gene Sequencing

  2011cited by this paper
• Integrated Genomic Analyses of Ovarian Carcinoma

  2011cited by this paper
• Present and future of PI3K pathway inhibition in cancer: perspectives and limitations.

  2011cited by this paper
• Prognostic Impact of Concomitant p53 and PTEN on Outcome in Early Stage (FIGO I-II) Epithelial Ovarian Cancer

  2011cited by this paper
• Loss of Inhibitory Insulin Receptor Substrate-1 Phosphorylation Is an Early Event in Mammalian Target of Rapamycin–Dependent Endometrial Hyperplasia and Carcinoma

  2010cited by this paper
• PI(3)King Apart PTEN's Role in Cancer

  2010cited by this paper
• Prognostic value of microsatellite instability (MSI) and PTEN expression in women with endometrial cancer: results from studies of the NCIC Clinical Trials Group (NCIC CTG).

  2010cited by this paper
• PTEN Deficiency in Endometrioid Endometrial Adenocarcinomas Predicts Sensitivity to PARP Inhibitors

  2010cited by this paper
• Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary

  2010cited by this paper
• Mammalian target of rapamycin is a biomarker of poor survival in metastatic serous ovarian carcinoma.

  2010cited by this paper
• Prognostic value and clinicopathological significance of p53 and PTEN in epithelial ovarian cancers.

  2009cited by this paper
• PTEN promoter methylation and LOH of 10q22-23 locus in PTEN expression of ovarian clear cell adenocarcinomas.

  2009cited by this paper
• Loss of Phosphatase and Tensin homologue deleted on chromosome 10 engages ErbB3 and insulin-like growth factor-I receptor signaling to promote antiestrogen resistance in breast cancer.

  2009cited by this paper
• Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors

  2009cited by this paper
• Cancer Statistics, 2009

  2009cited by this paper
• Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer.

  2008cited by this paper
• From endometrial hyperplasia to endometrial cancer: insight into the biology and possible medical preventive measures

  2008cited by this paper
• The role of PTEN signaling perturbations in cancer and in targeted therapy

  2008cited by this paper
• KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab.

  2008cited by this paper
• Ovarialkarzinome

  2008cited by this paper
• Essential role for nuclear PTEN in maintaining chromosomal integrity.

  2007cited by this paper
• PTEN mutation, expression and LOH at its locus in ovarian carcinomas. Relation to TP53, K-RAS and BRCA1 mutations.

  2006influential reference
• Alteration and clinical relevance of PTEN expression and its correlation with survivin expression in epithelial ovarian tumors.

  2006cited by this paper
• Understanding interobserver agreement: the kappa statistic.

  2005cited by this paper
• Immunohistochemical analysis of PTEN in endometrial carcinoma: a tissue microarray study with a comparison of four commercial antibodies in correlation with molecular abnormalities

  2005cited by this paper
• Protein expression and prognostic value of genes in the erb-b signaling pathway in advanced ovarian carcinomas.

  2005cited by this paper
• Expression of PTEN in ovarian epithelial tumors and its relation to tumor behavior and growth.

  2005cited by this paper
• Reduced Expression of PTEN Protein and Its Prognostic Implications in Invasive Ductal Carcinoma of the Breast

  2005influential reference
• The Histologic Type and Stage Distribution of Ovarian Carcinomas of Surface Epithelial Origin

  2004cited by this paper
• AKT and mTOR phosphorylation is frequently detected in ovarian cancer and can be targeted to disrupt ovarian tumor cell growth

  2004cited by this paper
• Breast cancer--loss of PTEN predicts resistance to treatment.

  2004cited by this paper
• Cancer mortality in Europe, 1995–1999, and an overview of trends since 1960

  2004cited by this paper
• Tumour suppressor gene expression correlates with gastric cancer prognosis

  2003cited by this paper
• Expression and prognostic role of tumor suppressor gene PTEN/MMAC1/TEP1 in hepatocellular carcinoma

  2003cited by this paper
• Expression of PTEN in renal cell carcinoma and its relation to tumor behavior and growth

  2003cited by this paper
• Loss of PTEN expression is associated with metastatic disease in patients with endometrial carcinoma

  2002cited by this paper
• Systematic review of first-line chemotherapy for newly diagnosed postoperative patients with stage II, III, or IV epithelial ovarian cancer.

  2002cited by this paper
• Frequent loss of PTEN expression is linked to elevated phosphorylated Akt levels, but not associated with p27 and cyclin D1 expression, in primary epithelial ovarian carcinomas.

  2001cited by this paper
• PTEN mutation located only outside exons 5, 6, and 7 is an independent predictor of favorable survival in endometrial carcinomas.

  2001cited by this paper
• PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme.

  2001cited by this paper
• Frequent activation of AKT2 and induction of apoptosis by inhibition of phosphoinositide-3-OH kinase/Akt pathway in human ovarian cancer

  2000cited by this paper
• PTEN mutation in endometrial cancers is associated with favorable clinical and pathologic characteristics.

  1998cited by this paper
• Frequent PTEN/MMAC mutations in endometrioid but not serous or mucinous epithelial ovarian tumors.

  1998cited by this paper
• Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers

  1997cited by this paper
• PTEN, a Putative Protein Tyrosine Phosphatase Gene Mutated in Human Brain, Breast, and Prostate Cancer

  1997cited by this paper
• Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer

  1996cited by this paper
• Loss of the chromosomal region 10q23-25 in prostate cancer.

  1995cited by this paper
• Molecular genetics for the clinician

  1993cited by this paper
• Cancer statistics

  1989cited by this paper
• Open Access Research Article Expression Signatures of Tp53 Mutations in Serous Ovarian Cancers

  year unknowncited by this paper

• PTEN Deficiency in Tubo-Ovarian High-Grade Serous Carcinoma is Associated with Poor Progression-Free Survival and is Mutually Exclusive with CCNE1 Amplification.

  2023cites this paper
• A Randomised, Multi-centre Phase II Trial of Weekly Paclitaxel and Vistusertib in Platinum-Resistant Ovarian High-Grade Serous Carcinoma: OCTOPUS Arm 1

  2022cites this paper
• The Hallmarks of Ovarian Cancer: Actionable Genetics, Targetable Pathways, and Predictive Biomarkers

  2021cites this paper
• Activation of the Akt/mammalian target of rapamycin pathway in combined hepatocellular carcinoma and cholangiocarcinoma: significant correlation between p-4E-BP1 expression in cholangiocarcinoma component and prognosis

  2020cites this paper
• PTEN and Gynecological Cancers

  2019cites this paper
• Precise Immunodetection of PTEN Protein in Human Neoplasia.

  2019cites this paper
• Nuclear β-Catenin Localization and Mutation of the CTNNB1 Gene: A Context-Dependent Association

  2018cites this paper
• PTEN/PI3K/AKT protein expression is related to clinicopathological features and prognosis in breast cancer with axillary lymph node metastases.

  2017cites this paper
• Beside P53 and PTEN: Identification of molecular alterations of the RAS/MAPK and PI3K/AKT signaling pathways in high-grade serous ovarian carcinomas to determine potential novel therapeutic targets

  2016influential citation
• Étude des mutations des gènes KRAS, NRAS, BRAF, PIK3CA, MET et de l’expression des protéines P53 et PTEN et leurs implications cliniques dans le carcinome ovarien de haut grade

  2016influential citation
• First application of the Automated QUantitative Analysis (AQUA) technique to quantify PTEN protein expression in ovarian cancer: A correlative study of NCIC CTG OV.16.

  2016cites this paper
• Aberrant NHERF1 expression as a biomarker in lung carcinoma

  2016cites this paper